Last reviewed · How we verify
Ocufen (flurbiprofen)
Ocufen (flurbiprofen) is a nonsteroidal anti-inflammatory drug (NSAID) developed by Allergan and currently owned by Pharmacia And Upjohn. It targets prostaglandin G/H synthase 1 to reduce inflammation and pain. Ocufen is approved to treat osteoarthritis, rheumatoid arthritis, and prevent ocular surgery-induced miosis. The drug is off-patent, with multiple generic manufacturers available. It has a high bioavailability of 92%.
At a glance
| Generic name | flurbiprofen |
|---|---|
| Sponsor | Pfizer |
| Drug class | Nonsteroidal Anti-inflammatory Drug |
| Target | Prostaglandin G/H synthase 1 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1986 |
Approved indications
- Osteoarthritis
- Prevention of Ocular Surgery-Induced Miosis
- Rheumatoid arthritis
Common side effects
- Increased bleeding tendency of ocular tissues
- Fibrosis
- Miosis
- Mydriasis
- Transient burning and stinging upon instillation
- Other minor symptoms of ocular irritation
Drug interactions
- fluconazole
- lithium
- methotrexate
- phenprocoumon
- voriconazole
- warfarin
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- The Aim of This Study is to Compare the Effects of Two Different Topical Agents (KLOROBEN® and KLORHEX PLUS®) Used in the Surgical Extraction of Mandibular Bilateral Mesioangular Impacted Third Molars on Postoperative Pain, Edema, and Trismus. (NA)
- Efficacy of Flurbiprofen Spray for Postoperative Sore Throat Following Double-Lumen Endobronchial Intubation (NA)
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- Osellidine is Used for Analgesia During Daytime Hysteroscopic Surgery
- Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects (PHASE1)
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocufen CI brief — competitive landscape report
- Ocufen updates RSS · CI watch RSS
- Pfizer portfolio CI